Unichem Laboratories Ltd

- The transcript does not mention any current or planned fundraising through debt or equity. - There is no discussion about raising additional capital via equity issuance or debt financing. - Capex plans involve around Rs. 200 Crores primarily for the Kolhapur API facility, funded internally. - Provisions and investments are discussed, but no mention of external fundraising. - Overall, no indication of new debt or equity fundraising in the near term based on the provided call transcript.

- The company is aggressively investing in capex, with over Rs. 50 Crores spent in the current quarter mainly for the Kolhapur unit. - Planned capex for FY2017-2018 is around Rs. 200 Crores, primarily directed toward the API facility in Kolhapur, along with maintenance capex, R&D, and biosimilars-related costs. - The Kolhapur plant is expected to start commercial production from Q1 FY2018, initially catering to ROW and domestic markets, with plans for US FDA and UK MHRA approvals thereafter. - Capitalization of the Kolhapur facility is expected in FY2018. - Provisions have been made for the Brazilian subsidiary, with Rs. 7 Crores provided quarterly as a cautious accounting policy; this investment is reversible with improved revenues. - No specific mention of other strategic investments beyond these points.

- Domestic business is expected to show robust double-digit growth for FY2017, continuing the positive trajectory with better monsoon impact aiding acute business. - Exports, particularly to the US market, are expected to grow better than last year due to expanded capacities and recent approvals. - US business aims to maintain a growth rate of around 30-40% for fiscal 2017 and is confident about continuing similar growth in fiscal 2018, contingent on product approvals. - Volume growth in domestic formulations was around 6%, with price growth also near 6% in Q1 FY2017; new product launches planned in Q2 FY2017. - Post-capitalization of the Kolhapur API plant (expected FY2018), API sales to third parties and ROW market supplies are expected to improve. - Unienzyme’s move to OTC market is expected to scale up revenues and bottom-line in domestic formulations. - Overall margin improvement anticipated due to operating leverage from expanded capacity, especially in the US market.

- Domestic business is expected to continue robust double-digit growth for the financial year, driven by better monsoon and strong volume and price growth (~6% each in Q1). - US business aims at maintaining a 30-40% growth rate in fiscal 2017 and fiscal 2018, contingent on product approvals. - Margin improvement is anticipated due to operating leverage from expanded capacities, especially in the US market. - The Kolhapur API facility commissioning in Q1 FY18 will support growth and improve third-party API sales. - Marketing investments, especially for OTC products like Unienzyme, will increase from FY18 onward, potentially boosting domestic formulations growth. - Provisions in subsidiaries like Brazil are reversible; improvements in these markets could positively impact consolidated profits. - Overall, the company is confident about growth in revenues, margins, and profitability over FY17 and FY18.

The transcript does not explicitly mention any details regarding the current or expected order book or pending orders for Unichem Laboratories. The discussion primarily focuses on: - Product launches, especially three products to be launched in the next 2-3 quarters. - US market approvals and filings. - Domestic market initiatives including moving Unienzyme to OTC. - Capex and commissioning timelines for the Kolhapur plant. - Growth guidance and revenue breakdown. - Provisions related to the Brazilian subsidiary. - No specific mention or updates on order book or pending order status. Therefore, no information is available in the provided pages regarding the current or expected order book or pending orders.